Comparison O
with O
alkaline I-GENE
phosphatases I-GENE
and O
5 I-GENE
- I-GENE
nucleotidase I-GENE

Pharmacologic O
aspects O
of O
neonatal O
hyperbilirubinemia O
. O

When O
CSF O
[ O
HCO3 O
-] O
is O
shown O
as O
a O
function O
of O
CSF O
PCO2 O
the O
data O
of O
K O
- O
depleted O
rats O
are O
no O
longer O
displaced O
when O
compared O
to O
controls O
but O
still O
have O
a O
significantly O
greater O
slope O
( O
1 O
. O
21 O
+/- O
0 O
. O
23 O
vs O
. O

Flurazepam O
thus O
appears O
to O
be O
an O
effective O
hypnotic O
drug O
with O
the O
optimum O
dose O
for O
use O
in O
general O
practice O
being O
15 O
mg O
at O
night O
. O

Beta O
blocking O
agents O
. O

When O
extracorporeal O
CO2 O
removal O
approximated O
CO2 O
production O
( O
VCO2 O
), O
alveolar O
ventilation O
almost O
ceased O
. O

Intravenous O
administration O
( O
25 O
mg O
/ O
kg O
) O
of O
carbonic I-GENE
anhydrase I-GENE
inhibitors O
( O
acetazolamide O
, O
methazolamide O
, O
dichlorphenamide O
, O
sulthiame O
) O
induced O
an O
early O
important O
rise O
of O
cortical O
p O
O2 O
, O
which O
is O
not O
dependent O
on O
increase O
of O
p O
O2 O
and O
p O
CO2 O
and O
decrease O
of O
pH O
in O
arterial O
blood O
. O

Teratological O
study O
of O
etoperidone O
in O
the O
rat O
and O
rabbit O
. O

Colorectal O
polyps O
should O
be O
removed O
endoscopically O
whenever O
possible O
. O

The O
variable O
HMG I-GENE
dosage O
regimen O
was O
found O
to O
offer O
no O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
